US LNG exports surge but will buyers in China turn up?
InfuSystem Holdings, Inc. (NYSE American:INFU) announced that on Tuesday it entered into a Second Amendment to its Credit Agreement with JPMorgan Chase (NYSE:JPM) Bank, N.A., acting as administrative agent, and participating lenders. According to a statement based on a press release and SEC filing, the amendment extends the maturity date of the company’s existing credit facility to July 15, 2030.
The original Credit Agreement was established on February 5, 2021, and was previously amended before this latest extension. The agreement involves InfuSystem Holdings and its direct and indirect subsidiaries as borrowers. The company is incorporated in Delaware and is headquartered in Rochester Hills, Michigan. With annual revenue of $138 million and a perfect Piotroski Score of 9, as reported by InvestingPro, the company demonstrates strong operational efficiency.
The filing states that the amendment was executed by the company and all relevant subsidiaries and loan parties. Details regarding other changes to the terms of the credit facility, if any, were not disclosed in the filing.
This information is based on a press release statement and documents submitted to the Securities and Exchange Commission.
In other recent news, InfuSystem Holdings Inc. reported its Q1 2025 earnings, showing a slight miss on earnings per share (EPS) but surpassing revenue expectations. The company reported an EPS of -$0.01, falling short of the forecasted $0.02, while revenue reached $34.7 million, exceeding the anticipated $34.07 million. Revenue rose by 8.5% year-over-year, and adjusted EBITDA increased by 64% compared to the previous year. The company maintains a positive outlook, expecting full-year revenue growth between 8% and 10%. InfuSystem is investing in IT systems upgrades and expanding its biomed services. The focus remains on capital-efficient growth and improving profitability. Despite the EPS miss, the revenue beat reflects operational efficiencies and strategic growth in key segments. The company is well-positioned in the medical device distribution sector with significant growth in its oncology and wound care segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.